Allied Market Research Projects $26+ Billion Bleeding Disorders Market by 2032

According to a report by Allied Market Research titled “Bleeding Disorders Market,” the global market was valued at $13.8 billion in 2022 and is projected to reach $26 billion by 2032, with a compound annual growth rate (CAGR) of 6.6% from 2023 to 2032. The report categorizes the market by disease type (including hemophilia A, hemophilia B, Von Willebrand disease, and others), treatment type (such as factor replacement therapy and drug therapy), and distribution channels (hospital pharmacies, drug stores & retail, and others).

Download Sample Copy – https://www.alliedmarketresearch.com/request-sample/2801

Prime determinants of growth  

The primary drivers of growth in the global bleeding disorder market include the escalating prevalence of conditions like hemophilia A & B, leading to heightened demand for antihemophilic drugs. Additionally, increased funding for research and development endeavors aimed at pioneering novel therapies for treating bleeding disorders acts as a significant catalyst. Nonetheless, challenges such as the steep cost of hemophilia treatment and the potential for serious adverse effects linked with plasma-derived products are poised to impede market growth. Conversely, the upsurge in healthcare expenditure and the pressing unmet medical needs for enhanced treatment options, particularly in developing nations, are anticipated to unlock substantial opportunities for market expansion in the foreseeable future.

Leading Market Players: – 

• Bayer AG
• CSL Ltd. (CSL Behring)
• F. Hoffmann-La Roche AG
• Grifols, S.A.
• Medexus Pharma Inc.,
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• SANOFI Corporation
• Takeda Pharmaceutical Company Limited

The hemophilia A segment to maintain its leadership status throughout the forecast period 

In 2022, the hemophilia A segment dominated the global bleeding disorder market, capturing nearly half of the market revenue. This segment is projected to sustain its leading position throughout the forecast period, primarily due to the rising prevalence of hemophilia A and heightened research and development efforts aimed at pioneering innovative therapies for its treatment. Moreover, this segment is anticipated to exhibit the fastest compound annual growth rate (CAGR) of 7.1% from 2023 to 2032, underscoring its significance in driving market expansion.

The factor replacement therapy segment to maintain its leadership status throughout the forecast period 

Based on treatment type, the factor replacement therapy segment held the highest market share in 2022, accounting for nearly three-fifths  of the global bleeding disorder market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to an increase in the prevalence of severe hemophilic patients and surge in number of research & development activities, and increase in number of clinical trials, for the development of novel factor replacement therapy based drugs. The same segment would cite the highest CAGR of 6.7% during forecast period.

North America to maintain its dominance by 2032 

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for more than half of the global bleeding disorder market revenue, and is likely to dominate the market during the forecast period. This is attributed to surge in cases of bleeding disorder, strong presence of key players, and availability of advanced healthcare system & modern medical technologies. However, the Asia-Pacific region is expected to witness the fastest CAGR of 8.0%  from 2023 to 2032 , owing to the presence of large hemophilia patient population, rise in demand of drugs of bleeding disorder due to high population base, and increase in public–private investments for unmet medical needs.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/2801